Sustainable Enzyme Engineering Will Power Expanding Biopharma Opportunities
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
10 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$11.00
73.8% undervalued intrinsic discount21 Aug
US$2.89
1Y
-5.4%7D
-4.2%